Purity and potency answer different questions and are measured by different means. Purity asks what fraction of detected material is the target compound, determined chromatographically. Potency asks what biological activity the material produces, determined in a functional assay. A batch can satisfy a 99% purity specification and still show reduced activity, because the properties that produce activity are not the properties chromatography measures. This guide covers where the two diverge, what causes the gap, and what establishes activity when a purity number cannot.
Two different measurements
Chromatographic purity is a ratio: target peak area divided by total integrated peak area from an HPLC run, describing composition among UV-detected species under one method's conditions. Potency is a functional readout, typically an EC50, IC50, or comparable parameter from a receptor binding or cell-based assay, describing what the material does in a defined system. The two are related but not equivalent, and the relationship is asymmetric in a useful way. Low purity raises risk and muddies attribution, since substantial non-target content leaves open what produced a given functional result, even when the readout itself looks normal. High purity does not reliably predict activity, because it constrains composition without constraining conformation, aggregation state, or actual peptide mass per vial. That asymmetry is why purity works well as a screening criterion and poorly as an activity guarantee.
Conformation and aggregation
Peptide activity depends on three-dimensional structure, and structure is largely invisible to reverse-phase chromatography. A peptide that has adopted a non-native conformation, or that has aggregated into dimers and higher-order assemblies, may present the same mass and similar hydrophobicity while being functionally unavailable. Aggregation is the most common mechanism behind an activity gap. It develops during lyophilization, through freeze-thaw cycling, or in concentrated storage, and hydrophobic sequences are the most susceptible. The analytical wrinkle is that reverse-phase conditions can dissociate aggregates: the denaturing mobile phase pulls assemblies apart before detection, so aggregated material is counted as monomer and the purity figure looks unaffected. Size-exclusion chromatography, which separates by hydrodynamic size under non-denaturing conditions, is the method that sees this directly. A batch reporting 99% by reverse-phase HPLC and showing significant high-molecular-weight species by size exclusion is exactly the case where purity and potency come apart.
Peptide content versus purity
A second gap is arithmetic rather than structural. Chromatographic purity is a share of UV-detected material and excludes species that do not absorb meaningfully at the detection wavelength, which means water, residual salts, and counterions fall outside the calculation entirely. Lyophilized peptides are often hygroscopic and carry counterion load from purification, so the mass in a vial can include a substantial non-peptide fraction while the purity figure remains high. When a protocol calculates concentration from vial mass, that fraction becomes a systematic error: less compound is present than assumed, which reads as reduced potency even though the material is exactly what the certificate says it is. This failure mode is common and entirely avoidable. Content measures such as amino acid analysis, or determining concentration in-house after solubilization, resolve it. Requesting a higher purity specification does not, because purity was never the quantity in question.
Related substances with partial activity
The third mechanism runs the opposite direction and can inflate apparent potency rather than reduce it. Deletion sequences, oxidized variants, and diastereomers share most of the target's structure, and some retain partial affinity for the same receptor. Material containing such impurities produces a functional result reflecting a mixture rather than a single compound, which is a problem for interpretation even when the aggregate activity looks reasonable. Diastereomers deserve particular attention here because they are the hardest impurity class to detect: identical mass makes them invisible to mass spectrometry, and they frequently co-elute with the target in reverse-phase chromatography, so a high purity figure carries no information about stereochemical integrity. Since activity depends on three-dimensional fit, a stereochemically compromised batch can meet every routine specification and still behave differently in a binding assay. Chiral chromatography is what addresses this directly, with circular dichroism as a bulk-level supporting check, and neither is run routinely unless specified.
Handling and time
Both purity and potency are properties measured at a moment, and potency can degrade on a shorter timescale. Oxidation of methionine, cysteine, or tryptophan residues progresses during storage and can reduce binding without producing a dramatic change in a chromatographic figure. Aggregation accumulates through repeated freeze-thaw cycles and container openings. Hydrolysis and deamidation proceed slowly in improperly stored material. A certificate issued at production describes the batch at that point, and the interval between testing and use, along with the conditions across it, sits entirely outside the document. This is why a purity figure from months earlier is weak evidence about current activity, and why storage discipline and handling logs belong alongside the certificate in any assessment of why a batch underperformed.
Establishing activity when it matters
Where functional performance is the actual requirement, it has to be measured rather than inferred. A reference-standard comparison is the most direct approach: run the batch alongside material of known activity in the same assay on the same day, which controls for assay drift and produces a relative potency figure that is interpretable. Orthogonal characterization supports the interpretation, meaning size-exclusion chromatography for aggregation state, a content measure for actual peptide mass, and a stereochemical method where the sequence carries chiral risk. Consistency checks across lots matter for longitudinal work, since a change in relative potency between batches at constant reported purity localizes the problem to something purity does not measure. Practically, the recommendation is to keep purity as the screening criterion it is good at being, and to add a functional check whenever conclusions depend on activity rather than identity. The chromatogram behind the purity figure is worth reading in parallel, as covered in the guide to reading HPLC chromatograms.
FAQ
Can a batch be 99% pure and still show low activity?
Yes. Aggregation, non-native conformation, and high non-peptide content in the vial all reduce functional activity without necessarily lowering a reverse-phase purity figure.
Why does aggregation not show up in the purity number?
Reverse-phase mobile phase conditions can dissociate aggregates before detection, so the material is counted as monomer. Size-exclusion chromatography under non-denaturing conditions detects it.
Is low purity ever compatible with normal activity?
It can be, if the impurities are inert relative to the assay. But low purity makes results harder to attribute, so it remains a poor foundation even when activity appears normal.
How is potency actually measured?
In a functional assay, typically as an EC50 or IC50, ideally against a reference standard of known activity run in the same session to control for assay variability.
Do suppliers provide potency data?
Rarely for research-grade material. Certificates generally cover identity and purity only, so functional characterization is usually the receiving laboratory's responsibility.
Research Use Only: All compounds sold by Prove It Performance are intended exclusively for laboratory research. Not for human or animal consumption. These products are not drugs, supplements, or food. Statements have not been evaluated by the FDA. Must be 21+ to purchase.
Stay in the loop
New compounds, research updates & exclusive subscriber deals.
